|Home | About | Journals | Submit | Contact Us | Français|
Correspondence to: Stavros Dimopoulos, MD, Cardiopulmonary Exercise Testing and Rehabilitation Laboratory, 1st Critical Care Medicine Department, Evaggelismos Hospital, National and Kapodistrian University of Athens, 10676 Athens, Greece. rg.aou.dem@uci-a
Telephone: +30-697-3956974 Fax: +30-213-2041888
Circulating bone-marrow-derived cells, named endothelial progenitor cells (EPCs), are capable of maintaining, generating, and replacing terminally differentiated cells within their own specific tissue as a consequence of physiological cell turnover or tissue damage due to injury. Endothelium maintenance and restoration of normal endothelial cell function is guaranteed by a complex physiological procedure in which EPCs play a significant role. Decreased number of peripheral blood EPCs has been associated with endothelial dysfunction and high cardiovascular risk. In this review, we initially report current knowledge with regard to the role of EPCs in healthy subjects and the clinical value of EPCs in different disease populations such as arterial hypertension, obstructive sleep-apnea syndrome, obesity, diabetes mellitus, peripheral arterial disease, coronary artery disease, pulmonary hypertension, and heart failure. Recent studies have introduced the novel concept that physical activity, either performed as a single exercise session or performed as part of an exercise training program, results in a significant increase of circulating EPCs. In the second part of this review we provide preliminary evidence from recent studies investigating the effects of acute and long-term exercise in healthy subjects and athletes as well as in disease populations.
Τhe process of blood vessel formation occurs by two different mechanisms, angiogenesis and vasculogenesis. Angiogenesis describes blood vessel growth from existing blood vessels by sprouting of differentiated endothelial cells or intussusceptions of existing capillaries[1,2]. In contrast, vasculogenesis is defined as blood vessel growth from in situ differentiating angioblasts. Until recently, it has been assumed that vasculogenesis is limited to embryogenesis. For the first time in 1997, Asahara et al described the existence of endothelial cells in the peripheral blood of adults derived from the bone marrow, and confirmed the role of vasculogenesis during the process of postnatal neovascularization. Hematopoietic stem cells that give rise to blood cells and move between bone marrow and peripheral blood are the best-characterized adult stem cells in humans. This circulating bone-marrow-derived cell population has been named endothelial progenitor cells (EPCs). There are at least two different types of EPCs population, early and late. Early EPCs are usually referred to as the angiogenic EPC population obtained from short-term cultures of 4-7 d. Late EPCs, often called outgrowth EPCs, have different growth patterns and are usually obtained from long-term cultures of at least 2-4 wk. These cells are capable of maintaining, generating, and replacing terminally differentiated cells within their own specific tissue as a consequence of physiological cell turnover or tissue damage due to injury.
Endothelial cell injury, after tissue ischemia or vascular injury, initiates physiological processes of reparation and regeneration. The initial step is the mobilization of EPCs from the bone marrow into peripheral blood, which is followed by the recruitment of EPCs to the site of tissue ischemia or vascular injury (Figure (Figure1).1). Locally, vasculogenesis occurs after EPC adhesion and migration into the newly formed vascular network and differentiation into mature endothelial cells. The pathophysiology mentioned above is critical in terms of endothelium maintenance and restoration of normal endothelial cell function.
The current literature suggests that adult stem cells generate differentiated cells beyond their own tissue boundaries, a process termed “developmental plasticity”. Circulating EPCs play two major roles, endothelial healing and neoangiogenesis[9,10].
For more than 10 years researchers as well as clinicians have focused on understanding the physiological and pathophysiological role of the EPCs in the cardiovascular system and in cardiovascular disease, because endothelial dysfunction has been established as an independent prognostic risk factor for cardiovascular disease[11,12]. Although there are no clear definition criteria for accurate identification of EPCs so far, there have been several studies indicating the important role of EPCs in restoring endothelial damage. Decreased numbers of EPCs have been associated with endothelial dysfunction and high cardiovascular risk[5,14].
Promotion of recruited bone-marrow-derived EPCs is the primary mechanism for endothelial replacement in areas of vascular damage as demonstrated in animal models. In these experimental ischemic injuries, bone-marrow-derived cells play an important role in vascular repair and regeneration enhancing tissue recovery[15-17].
EPCs are present in peripheral blood circulation of healthy adult subjects, although in small numbers and are responsible for vascular and endothelial repair after tissue damage. A decrease in EPC levels was shown to inversely correlate with the occurrence of endothelial dysfunction[5,19].
It has been also documented that EPCs are significantly reduced in elderly populations, and appear to have elevated apoptotic susceptibility. The number and function of early EPCs isolated from the peripheral blood of 20 healthy young and 20 old (61 ± 2 years) individuals have been investigated by Heiss et al. Early EPCs from the old subjects were found to be significant impaired in terms of fundamental functional features like proliferation, migration and survival, although no quantitative differences in EPCs were observed. Chronic treatment with bone-marrow-derived progenitor cells from young non-atherosclerotic ApoE-/- mice prevents atherosclerosis progression in ApoE-/- mice recipients despite persistent hypercholesterolemia. In contrast, treatment with bone marrow cells derived from older ApoE-/-mice is much less effective. Similarly, transplantation of bone-marrow-derived EPCs from young, but not old donor mice prevented a decline in the angiogenic platelet-derived growth factor signaling and cardiac angiogenesis in an aging murine model. Despite these well-documented experimental studies on EPCs in aging populations, the mechanisms are still unknown and further research is needed.
The activity and migratory capacity of EPCs is reduced in patients with coronary heart disease. Furthermore it has been shown that EPCs enhance angiogenesis, promote vascular repair, improve endothelial function, inhibit atherosclerosis and increase ventricular function after myocardial infarction[5,9,30-32]. All these findings indicate that the number of EPCs may be a marker of cardiovascular risk. EPCs levels were also inversely correlated with the occurrence of in-stent restenosis.
Very few research groups have studied circulating EPCs levels in chronic heart failure (CHF). Specifically, it has been shown that EPC mobilization occurs in a biphasic pattern in CHF; increased in mild stages, and depressed in advanced CHF[34,35]; possibly due to the myelosuppressive role of cytokines such as tumor necrosis factor-α in severe CHF. A significant progressive increase of EPCs was noted in patients admitted with acute exacerbation concomitantly with their clinical amelioration during hospitalization.
Interestingly, Geft et al have studied early and late apoptotic progenitor cells in CHF, showing that severe heart failure patients exhibited higher numbers of late apoptotic progenitors, and there was a significant association of the latter cells with disease severity. However, in another clinical study, the authors reported that there was no correlation between CD34+ circulating cells and New York Heart Association (NYHA) functional class.
Further research is needed to clarify the clinical significance of EPCs levels and their role in CHF patients in relation to acute exacerbations and disease severity.
Over the past 4 years a few studies investigated the role of left ventricular assist device (LVAD) implantation in the number of EPCs in patients with end-stage CHF (NYHA class III or IV). In a recent study, Jahanyar et al have demonstrated that LVADs cause a significant increase of stem cell factor and its receptor (c-kit) gene expression, which coincided with a surge of mast cells after ventricular unloading. In another study, a significant increase in EPCs was also reported after LVAD implantation.
Both studies were limited by the small number of participants and the lack of an adequate control group. In the study of Jahanyar et al the patients’ EPCs were compared to tru-cut biopsies of donor hearts, while in the study of Manginas et al, the control group comprised patients who were ineligible for LVAD implantation.
In addition, in an experimental study, the research group found that the intramuscular injection of EPCs [in particular KLS cells (Lin-–/c-kit+/Sca1+)] in the LV-unloading heart of rodents, may have a protective effect against cardiac systolic dysfunction and myocardial atrophy. The latter study suggests that this intervention may have a clinical potential as a combination therapy together with LVAD implantation.
Besides the nature of the study populations with the methodological flow limiting results, it seems that LVAD implantation increases EPC levels.
Endothelial dysfunction is strongly involved in the pathophysiology of pulmonary arterial hypertension (PAH). For this reason a growing interest has been recently raised in the role of EPCs in PAH. In a study of Smadja et al, the number of circulating endothelial cells was significantly higher in 10 patients with irreversible PAH than in 16 patients with reversible PAH and five control subjects, while progenitor cells did not differ among the groups. To make things more confusing it has also been reported that a significant decrease was observed in circulating EPCs in 20 patients with idiopathic PAH compared to 20 healthy controls. Accordingly, Hansmann et al reported that EPC numbers were 50% lower in PAH subjects versus matched controls.
In contrast with previous studies mentioned above it has been reported that EPCs were increased in patients with PAH compared with controls. In a recent clinical trial, where nine patients with PAH, nine patients with chronic thromboembolic pulmonary hypertension (CTEPH), and seven subjects with normal pulmonary arterial pressure were enrolled, the researchers concluded that EPCs were significantly increased in PAH patients compared to CTEPH and controls.
The results from the above studies appear conflicting, thus, further research is needed to clarify the role of EPCs in PAH. Research on EPCs should target on the different PAH stages, and the PAH diagnosis duration that might differentiate in terms of number and function.
In 2001, an increased number of EPCs in patients with sepsis and septic shock was found compared to healthy subjects. These findings were confirmed in a more recent study by Rafat et al. They reported that after studying 32 intensive care unit patients with sepsis, 15 patients without sepsis and 15 healthy controls, the number of EPCs was not only significantly higher in septic patients compared to non-septic patients and controls, but was also associated with survival. In a methodologically similar study, Burnham et al have shown that increased number of EPCs was highly correlated with improved survival in patients with early acute lung injury. In addition, in a prospective study enrolling 44 patients with ventilator-associated pneumonia and sepsis, the research group concluded that EPCs count on day 1 was correlated with survival. These studies suggest that patients with sepsis appear to present with elevated EPCs numbers compared to healthy controls, and furthermore, that EPCs levels are strongly correlated with outcome.
To the best of our knowledge, only a few studies[52-54] have investigated the number of EPCs in patients with chronic obstructive pulmonary disease (COPD). Methodological differences might have played a significant role in the fact that the studies had conflicting results. Peinado et al conducted dissection on pulmonary arteries of lung specimens of 15 patients undergoing lung resection because of carcinoma and compared the EPC numbers in nine subjects with moderate to severe COPD to the six subjects free of COPD. The authors concluded that EPCs were significantly greater in number in COPD patients.
In contrast to that study, two other controlled studies[53,54] reported lower levels of EPCs in blood samples from COPD patients compared to controls. The number of EPCs was also strongly correlated to disease severity for both studies. In a study by Sala et al, the authors investigated the response of EPCs to episodes of exacerbation of COPD (ECOPD). After studying 35 patients hospitalized because of ECOPD, 44 COPD patients, 10 smokers free of COPD and 10 healthy non-smokers, they found a higher level of EPCs in the ECOPD group compared to the other groups. Just recently, it has been shown that there is an impaired EPC mobilization and colony-forming capacity in COPD patients with stageIand II lung cancer undergoing thoracic surgery. It seems that more evidence is necessary to understand better the role of EPCs in COPD due to the inconclusive results mentioned above.
Four controlled studies[57-60] have been conducted to investigate the number of EPCs in patients with obstructive sleep apnea (OSA), who lacked cardiovascular disease and were free of any other known cardiovascular risk factor. All studies had a small number of participants and reported conflicting results. El Solh et al by studying 14 subjects with OSA documented higher numbers of EPCs compared to 10 healthy controls. They also reported that an 8-wk treatment with continuous positive airway pressure (CPAP) therapy significantly reduced the levels of EPCs in the OSA patient group. The same research group a year later confirmed the above outcome by enrolling 35 OSA patients on 8 wk nasal CPAP therapy.
In another study that included 13 OSA patients and 13 controls, there was a reduced number of EPCs in patients with OSA compared to controls. However, other researchers found no significant differences in EPCs between OSA patients and controls.
The conflicting results of the above studies need further investigation with larger numbers of study participants before conclusions can be made for the possible role of EPCs in OSA. Disease severity might play a significant role in the EPCs level and should be further assessed.
In diabetic patients the EPC levels are significantly reduced compared to non-diabetic controls. Loomans and colleagues reported that the EPCs numbers were decreased in patients with type I diabetes, compared to EPCs levels in healthy subjects. Enrolling 74 patients with typeIdiabetes, EPCs counts were significantly lower in these patients compared to 80 healthy controls.
Similarly, other studies have also demonstrated that EPCs levels were lower in patients with diabetes mellitus type II compared to healthy controls[63-65]. Treatment with strict glycemic control and total cholesterol improvement increased EPCs numbers. There is strong evidence that patients with diabetes typesIand II appear to have lower EPCs numbers compared to healthy controls. Further research is needed demonstrating the beneficial effects of the potential increase in EPCs by certain therapeutic measures (diet, exercise training, antidiabetic drug treatment, etc.).
In a study of Ghani et al, there was a significant difference in EPC counts between stroke patients (acute stroke: median 4.75, range 0-33; stable stroke: median 7.25, range 0-43) and control subjects (median 15.5, range 4.3-50), independent of age. In contrast, Yip et al demonstrated that the levels of circulating EPCs did not differ between patients with ischemic stroke and normal control subjects. The authors also reported that in patients with acute ischemic stroke, the EPCs levels were significantly higher than in subjects at high cerebrovascular risk, but appeared to be lower in patients with severe neurological impairment. The research group stated that the inconsistency of their findings with the results of Ghani et al was due to the difference in the time interval for blood sampling between the studies.
There was a significant decrease in circulating CD34+ cell levels in 25 patients with a history of atherothrombotic cerebral ischemic events compared with age-matched controls. Colony forming units (CFUs) and outgrowth cell population as a subset of EPCs were significantly reduced in 75 patients with acute stroke, compared with 45 patients with chronic stroke and 40 age-matched control subjects. Moreover, patients with large artery atherosclerosis had much lower CFU numbers and functional activities than the ones with cardioembolism.
It has also been reported that the increase in circulating EPC levels after acute ischemic stroke is associated with good functional outcome and reduced infarct growth, suggesting that EPCs might participate in neurorepair after ischemic stroke. There are convincing data that ischemic stroke is strongly correlated with low EPC levels and that levels are strongly correlated with functional outcome in acute ischemic stroke.
Little information is available on EPC mobilization in patients with peripheral arterial disease (PAD). In 2008, Delva et al studied the number of EPCs by different methods in a carefully selected group of 45 patients with CAD along with 24 healthy subjects. In patients with PAD, by utilizing the dual-binding method, the number of circulating EPCs was significantly increased compared to that in healthy controls. On the contrary, while using fluorescence-activated cell sorting analysis the results were different, both CD34+ and CD133+ cell counts were significantly decreased compared to controls. The use of different methods in data collection may explain the discrepancy. Finally, CFUs were significantly increased in PAD compared to healthy subjects.
After studying 48 PAD patients and 22 patients without PAD the researchers concluded that EPC mobilization occurred in PAD and showed a biphasic response, with elevated EPC levels in the moderate phase and reduced EPC levels in the advanced phase. EPC levels were also associated with the levels of novel circulating biomarkers and several aspects of PAD, including the severity, progression and disease outcome.
As a result of the limited number of studies, further research is needed on the levels of EPCs in patients with PAD. It seems however, that there is an increase of EPC levels in the moderate phase and a decrease in the advance phase of PAD.
In the very early stage of hypertension a significant increase in circulating progenitor cells is associated with reactive oxygen species and oxidative stress. Vasa et al, after studying patients with CAD concluded that the migratory capacity of EPCs was reduced in those patients with hypertension, although their total number did not change significantly.
Additionally, only recently it has been demonstrated that the in vivo endothelial repair capacity of early EPCs is substantially impaired in patients with newly diagnosed pre-hypertension and hypertension as their only cardiovascular risk factor. Increased senescence of early EPCs in pre-hypertensive and hypertensive patients was related to abnormal EPCs endothelial repair capacity. In the same study there was not a significant difference in the numbers of EPCs and endothelial apoptotic microparticles in pre-hypertensive and hypertensive patients when compared with healthy controls. From this study emerges evidence that the endothelial repair capacity of early EPCs is substantially impaired in hypertensive patients.
It is well established that obesity is associated with decreased numbers of EPCs[75-79]. The number of circulating EPCs is lower in obese compared with overweight and normal weight subjects, while EPCs colony forming capacity is blunted in overweight and obese compared with normal weight subjects. Tobler et al also stated that reduced numbers of EPCs along with their premature senescence might contribute to the development and progression of vascular dysfunction in obesity. Furthermore, the function of EPCs in obesity is impaired either by the impaired ability of circulating EPCs to release proangiogenic growth factors compared with normal weight adults and by the lower EPC resistance to an apoptotic stimulus in overweight and obese compared to normal weight. Interestingly, low EPCs levels and their functional deficiency can be reversed after significant weight reduction.
A summary of the above studies of EPCs in different disease populations is reported in Table Table11.
It is well recognised that physical activity has significant beneficial effects on overall health, and especially on cardiovascular morbidity and mortality. Physical inactivity is an independent risk factor for the development of coronary heart disease, stroke and peripheral vascular disease.
Regular physical activity significantly attenuates the atherosclerotic process by reducing atherosclerotic risk factors, retarding arterial wall aging[81,82], delaying development of endothelial dysfunction and preserving vascular function. Furthermore, physical training reduces vascular oxidative stress, increases the activity of endothelial nitric oxide synthase (eNOS) and results in increased blood flow to oxidative skeletal muscle fibers.
Accordingly, the beneficial effects of exercise have been reported in patients with CAD as part of the secondary prevention[86,87]. It is well known that physical training improves endothelial function and exercise capacity in patients with CAD, CHF and PAD. Exercise is also associated with improved body weight, blood pressure, insulin sensitivity and hemostatic and inflammatory variables[91,92]. High-intensity interval training is a relative novel alternative modality of exercise in metabolic syndrome, coronary heart disease and in CHF patients[95-97], allowing more intense stimuli in the peripheral muscles. The addition of strength training has been also shown to confer significant improvement in endothelial function[98,99] and peripheral microcirculation in CHF patients.
It has become common knowledge that exercise training has a significant therapeutic role in a vast majority of diseases. A structured exercise training program, and more specifically a combination of aerobic exercise (continuous or high-intensity interval training) with or without the addition of strength training can significantly attenuate the atherosclerotic process through its beneficial effects on endothelial function[93,95,98-100]. However, there is growing interest concerning the role of exercise training on EPCs that may interact with endothelium function; this issue is currently under investigation from several research groups in both healthy subjects and diseases.
Laufs et al in 2004 were the first research group to demonstrate that physical activity leads to an increased number of circulating EPCs in mice after 28 wk of running wheels. This effect occurred rapidly (7 d after training) and was sustained for at least 4 wk, providing evidence that EPC numbers can be increased by nearly threefold by exercise training. These findings were confirmed by another research group in a human study in which middle aged and older subjects following a 3 mo training program of walking, at moderate intensity, increased circulating angiogenic cell (CAC) migratory capacity by 50%. Accordingly, Yang et al showed that the number and activity of circulating EPCs of 10 older and 10 young sedentary healthy men were increased after 3 mo regular exercise. However, the increased number and activity of circulating EPCs of older sedentary healthy men was higher compared to the younger group. In contrast, in a study of 20 healthy men who followed a 6-wk interval exercise training program, [moderate (9 subjects) or high intensity (11 subjects)], there was no significant effect on EPC number in both groups, even though there was an improvement of vasoconstrictor function.
Furthermore, a study of 182 children (aged 11.1 ± 0.7 years) showed that physical activity by means of daily school exercise lessons can increase the number of circulating progenitor cells. More interestingly, EPC numbers decreased significantly after 10 d of detraining in highly active older men, even lower than the level of low-active (sedentary) men. These findings agree with the fact that sustained physical activity is necessary to preserve improved endothelial function for maintaining long-term training effects.
In an animal study, 8 wk of aerobic training in mice with advanced atherosclerotic lesions showed no improvement in atherosclerosis, whereas mice with early lesions benefited. The authors suggest that the impact of exercise on atherogenesis is primarily to retard the progression to advanced lesions, rather than reversing advanced lesions. Interestingly, the level of EPCs decreased, along with proinflammatory cytokines in response to exercise.
In another experimental study conducted in the early phase following traumatic brain injury in rats, the exercise group compared to the control group enhanced significantly proliferation of neural stem cells (NSCs) around the damaged area.
Despite the significant experimental study of Laufs et al, Luk et al showed that there was no significant increase in CD34/KDR+ EPCs after an 8-wk exercise training programme on 32 patients with CAD compared to controls. In contrast, in a recent uncontrolled study by Cesari et al, there was a significant increase in EPCs and a significant decrease in proinflammatory biomarkers, in patients with acute coronary syndrome, occurring after a 30-d period of cardiac rehabilitation (3 sessions per week of endurance training on a cycle ergometer, at 60%-70% of individual VO2 level obtained at peak exercise during baseline symptom-limited cardiopulmonary exercise testing). Because of the conflicting results and the small number of studies, more human studies are needed to clarify the possible beneficial effects of exercise on EPCs in CAD.
EPC levels [assessed as CD34+ cells coexpressing AC133 and vascular endothelial growth factor receptor 2 (VEGFR2), and as endothelial CFUs (e-CFUs)] were also evaluated in chronic renal failure patients on hemodialysis after a 6-mo walking exercise program. This study showed that there was not a significant change in CD34+ or CD34+/AC133+/VEGFR2+ cell numbers, but there was a significant change in e-CFUs.
A significant enhancement of circulating EPCs after 8 wk of supervised exercise training has also been demonstrated in CHF patients. In that study, 8 wk of detraining led to baseline EPC levels. In a recent study by Van Craenenbroeck et al similar results have emerged after investigating the effect of 6 mo exercise training in CHF, compared with a no exercise CHF group and a no exercise group of healthy subjects. The authors reported a reverse effect of exercise training on circulating angiogenic cell dysfunction and an increase in EPCs. An analogous increase in EPC numbers was found, after short-term exercise training (3 wk) in 14 CHF patients. The exercise program was a combination of calisthenics and aerobic exercise with an intensity up to 75%-85% of the maximum heart rate attained in the exercise test. The authors reported that even a relatively short-term exercise training program significantly improved the serum ability to support viability of EPCs as well as upregulation of proteins participating in LV remodeling.
Similarly, 37 CHF patients (LV ejection fraction 24% ± 2%) were randomly assigned to 12 wk of exercise training (n = 18) or sedentary lifestyle (n = 19). Exercise training increased the number of CD34+ progenitor cells from 1094 ± 677 to 1450 ± 798 cells/mL blood in the training group (P = 0.032 vs control). The number of CD34+/KDR+ EPCs was found to be augmented from 100 ± 127 to 183 ± 156 cells (P = 0.014 vs control) and their migratory capacity by 224 ± 263 vs -12 ± 159 CPCs/1000 plated CPCs in controls (P = 0.03).
The most recent paper on the effect of exercise training in patients with CHF is the one published by Mezzani et al. Patients (n = 30) with NYHA class II were allocated to either an aerobic 3-mo exercise training group or a control group, while seven age-matched healthy subjects were also studied. In addition to the previous studies, the authors reported that the numbers of EPCs, even though they did not differ between patient groups at baseline, significantly increased in the CHF training group, reaching values similar to those of healthy controls, while the difference between CHF controls and healthy controls did not reach statistical significance. Additionally, the levels of EPCs remained unchanged in the control patient group.
In a randomized controlled clinical trial, 40 patients with PAD were allocated to either an exercise or a control group. The intervention group followed a standardized training program twice a week for 6 mo. The initial duration included 35 min of intermittent walking, which was increased by 5 min each session until 50 min of intermittent walking was achieved. EPC levels were significantly increased and asymmetric dimethylarginine levels were decreased in the exercise group compared with the controls. The authors suggested an enhanced angiogenesis and improved endothelial function that might contribute to cardiovascular risk reduction.
The first study on the effect of exercise training in overweight and obese patients has recently been published by Cesari et al. Even though the study had a few methodological limitations, the authors reported a significant increase in all the three groups of EPCs (CD34+/KDR+: +33.3%; CD133/KDR+: +35%; CD34+/CD133+/KDR+: +35.7%) after a 3 mo exercise intervention program, compared to baseline measurements.
The underlying mechanisms of the effect of exercise training on EPC levels needs further investigation, but taken together with the existing data, it has been suggested that physical exercise increases NO bioavailability, and in parallel with this fact, the effect of physical activity on EPCs is markedly reduced after inhibition or deletion of eNOS, which suggests an NO-dependent increase in EPCs in response to exercise[101,113]. Additionally, it has been reported that physical exercise may increase EPC numbers by prolonging their lifespan. Data derived from cultured EPCs have indicated that the observed EPCs enhancement in the circulation and the bone marrow could be explained partly by antiapoptotic effects of physical activity on EPCs and potentially their progeny. The extra muscle stress that is additive to hypoxic stress and leads to a hypoxia-induced factor-1-mediated upregulation of both VEGF and stromal-cell-derived factor (SDF)-1 stimulated EPCs mobilization, as demonstrated by Sarto et al.
Even though the studies mentioned above followed different methodologies and exercise training protocols, we may assume that regular exercise training increases significantly circulating EPC levels, both in healthy subjects (rodents and humans) and in a variety of diseases. The strongest evidence so far in cardiovascular disease emerges from studies in CHF and PAD. More data are needed, however, to confirm the results of these preliminary studies and to investigate the optimum exercise protocol in order to maximize the possible beneficial effects.
The effect of a single exercise session on EPC levels has also been investigated. Rehman et al have demonstrated that exercise can acutely (within 5-10 min after completion of exercise) increase EPCs and CACs in 22 volunteer patients that underwent a symptom-limited treadmill or bicycle exercise test. It has been reported that a modified Bruce treadmill acute exercise protocol can significantly contribute to upregulation of circulating EPCs in healthy subjects. In the same study, the plasma NO levels were also increased and there was a significant linear relationship between the enhanced plasma NO levels and increased number of circulating EPCs activity after acute exercise.
Since that study, researchers have sought to investigate the effect of a single bout of strenuous exercise on late outgrowth endothelial cells (OECs). In a non-controlled study of 11 healthy, physically fit subjects, who followed 1 h of high-intensity (80% of the predicted maximum heart rate) aerobic exercise, the numbers of OEC colonies were doubled 1 h after exercise compared to baseline measurements. The OEC levels returned back to baseline levels 48 h after exercise. In another study, it was shown that strenuous exercise at 70% of the individual anaerobic threshold for 4 h could lead to a significant rise in progenitor cells (hematopoietic and EPCs).
In a recent study, exercise-induced changes in putative EPC gene expression were associated with thrombin production and the authors suggested that they may be increased by long-term exercise training. Moreover, in a study by Van Craenenbroeck et al, the authors analyzed the concentration of EPC levels before and immediately after a maximal cardiopulmonary exercise test, showing a significant increase of 50% in EPCs.
The acute effect of different exercise durations and intensities on EPC levels was also studied in healthy individuals. In that study, the authors reported that intensive and moderate aerobic exercise for 30 min but not for 10 min increased circulating levels of EPCs.
Furthermore, the analysis of EPC levels in 68 healthy marathon runners after finishing a marathon race, demonstrated no change compared to baseline levels. Similarly, in a more recent study, EPC levels were measured in a group of 10 healthy amateur runners after finishing a marathon and after completing a 1.5-km field test. The researchers observed no change in EPC levels after the marathon, while there was a significant increase after the field test. In addition, Goussetis et al showed a significant increase in inflammatory markers, which correlated with a rise in EPCs levels in amateur spartathlon runners (246 km). An interesting finding of this study was also the observation that endothelial cell colonies derived from mobilized EPCs contained significantly more cells 48 h after the race than those obtained in controls and in athletes before the race.
While studying a group of healthy young subjects, a group of healthy old and a group of patients with PAD after an acute exercise session, Shaffer et al concluded that young healthy individuals have an increased capacity to mobilize EPCs, as compared with older individuals. Interestingly, patients with PAD appeared to be unable to mount a significant increase in circulating EPCs, despite the ischemic stimulus. Van Craenenbroeck et al studied 41 CHF patients (22 mild, 19 severe) and 13 healthy subjects while performing a symptom limited cardiopulmonary exercise test. Even though there was no significant change in circulating CD34+ cells and CD34+/KDR+ progenitor cells, an improvement in CAC migratory capacity was most prominent in severe CHF, increased to levels that were no longer different from healthy controls. The same research group just recently sought to investigate whether the above result reflected an attenuated or delayed mobilization of EPCs, so they measured CD34+/KDR+ EPCs over a longer time period post-graded exercise testing (GXT). Even though the number of subjects was small (7 CHF patients and 8 healthy controls), the authors reported that EPC numbers increased within 10 min following GXT and remained elevated for up to 2 h. In CHF patients, the initial increase was small and normalized within 30 min.
From the current literature it emerges that the acute effect of a single exercise session, either performed as an exercise test, or as a single bout of strenuous exercise, can lead to a significant rise in EPCs in healthy subjects. On the contrary, there are still conflicting data with regard to long distance runners (e.g., marathon, spartathlon) and for this reason further investigation is required prior to definite conclusions. In CHF patients it seems that acute exercise might exert a rise in EPCs; however, the small number of studies with different exercise protocols, methodologies and the small number of study participants limit preliminary study results. Further investigational studies targeting on exercise characteristics (modality of exercise, intensity, duration, etc.) are also needed to elucidate the acute exercise effects on EPCs in CHF.
The mechanisms behind the exercise-induced mobilization of EPCs are not fully understood. In patients with cardiovascular disease, exercise-induced ischemia seems to stimulate augmentation of EPCs. In healthy subjects, tissue ischemia is not normally expected to occur due to exercise, but strenuous exercise at levels above what is defined as anaerobic levels, might induce oxidative stress and an inflammatory response and thus could stimulate the release of EPCs from the bone marrow[121,122]. Researchers have hypothesized[34,132] that, in an attempt to address vascular damage, EPCs show a compensatory increase in patients with mild to moderate CHF. Interestingly, VEGF and SDF are potent angiogenic factors that have been shown to increase after exercise sessions with concomitant rise in EPCs in cardiovascular disease, indicating a possible pathophysiological link. Therefore, endothelial factors, cytokines, bone-marrow-derived factors and oxidative stress are involved throughout exercise training and may explain exercise beneficial effects in health and cardiovascular disease.
In conclusion, recent studies provide evidence for the novel concept that physical activity, either performed as a single exercise session or performed as part of an exercise training program, results in a significant increase in circulating EPC levels. Moreover, in patients with cardiovascular disease, exercise training markedly improves vascular endothelium. However, future studies with larger sample sizes are required to investigate and confirm possible exercise training-induced EPCs rise in both healthy subjects and specific subsets, such as patients with hypertension, obesity, OSA, dyslipidemia, diabetes, CAD, PAD, or CHF. Studies should aim to characterize the optimum exercise regimen with regard to type, intensity and duration of exercise that may increase EPC levels. Confirming evidence will give the opportunity to the medical community to use a non-pharmacologic intervention, such as exercise, to mobilize EPCs. Revealing the mechanisms of exercise-induced EPC mobilization may result in the development of optimum exercise protocols to improve endothelial function and enhance angiogenesis.
Peer reviewers: Jesus Peteiro, MD, PhD, Unit of Echocardio-graphy and Department of Cardiology, Juan Canalejo Hospital, A Coruna University, A Coruna, P/ Ronda, 5-4º izda, 15011 A Coruña, Spain; Dr. Thomas Hellmut Schindler, Department of Medecine, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil, 4, 1211 Geneva, Switzerland
S- Editor Cheng JX L- Editor Kerr C E- Editor Li JY